Monday, February 6, 2023
Google search engine
HomeMarketResultsCentessa Pharmaceuticals plc (NASDAQ:CNTA) EVP Sells $22,164.60 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) EVP Sells $22,164.60 in Stock


Centessa Prescribed drugs plc (NASDAQ:CNTAGet Rating) EVP Antoine Yver offered 6,970 shares of the corporate’s inventory in a transaction on Wednesday, January 4th. The shares have been offered at a mean value of $3.18, for a complete worth of $22,164.60. Following the transaction, the chief vp now straight owns 751,913 shares within the firm, valued at $2,391,083.34. The sale was disclosed in a submitting with the Securities & Alternate Fee, which is on the market by this link.

Antoine Yver additionally not too long ago made the next commerce(s):

  • On Thursday, December 1st, Antoine Yver offered 9,400 shares of Centessa Prescribed drugs inventory. The shares have been offered at a mean value of $3.91, for a complete worth of $36,754.00.
  • On Tuesday, November 1st, Antoine Yver offered 9,700 shares of Centessa Prescribed drugs inventory. The shares have been offered at a mean value of $4.03, for a complete worth of $39,091.00.

Centessa Prescribed drugs Inventory Efficiency

Centessa Pharmaceuticals stock traded up $0.15 throughout mid-day buying and selling on Wednesday, reaching $3.28. 94,338 shares of the inventory traded palms, in comparison with its common quantity of 109,077. The inventory has a market capitalization of $310.27 million, a PE ratio of -1.29 and a beta of 0.40. The corporate has a debt-to-equity ratio of 0.18, a present ratio of 12.49 and a fast ratio of 12.49. Centessa Prescribed drugs plc has a 12-month low of $2.88 and a 12-month excessive of $11.19. The enterprise’s 50-day shifting common is $3.61 and its 200-day shifting common is $4.17.

Centessa Prescribed drugs (NASDAQ:CNTAGet Rating) final posted its quarterly earnings information on Thursday, November tenth. The corporate reported ($0.57) EPS for the quarter, lacking analysts’ consensus estimates of ($0.49) by ($0.08). As a bunch, sell-side analysts predict that Centessa Prescribed drugs plc will publish -2.22 EPS for the present fiscal yr.

Institutional Buying and selling of Centessa Prescribed drugs

Hedge funds have not too long ago purchased and offered shares of the corporate. Kynam Capital Administration LP elevated its place in Centessa Prescribed drugs by 179.9% throughout the first quarter. Kynam Capital Administration LP now owns 669,100 shares of the corporate’s inventory valued at $6,002,000 after buying a further 430,059 shares over the past quarter. JPMorgan Chase & Co. elevated its place in Centessa Prescribed drugs by 3,683.2% within the second quarter. JPMorgan Chase & Co. now owns 178,414 shares of the corporate’s inventory price $869,000 after shopping for a further 173,698 shares within the final quarter. Jane Avenue Group LLC bought a brand new stake in Centessa Prescribed drugs within the second quarter price about $192,000. Golden State Fairness Companions elevated its place in Centessa Prescribed drugs by 15.1% within the first quarter. Golden State Fairness Companions now owns 15,970 shares of the corporate’s inventory price $143,000 after shopping for a further 2,100 shares within the final quarter. Lastly, Prelude Capital Administration LLC bought a brand new stake in Centessa Prescribed drugs within the first quarter price about $102,000. Hedge funds and different institutional traders personal 78.03% of the corporate’s inventory.

Centessa Prescribed drugs Firm Profile

(Get Rating)

Centessa Prescribed drugs plc, a clinical-stage pharmaceutical firm, discovers, develops, and delivers medicines to sufferers. Its registrational pipeline merchandise embody Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that’s in Section III scientific growth for the therapy of autosomal dominant polycystic kidney illness; and SerpinPC, an activated protein C inhibitor, which is in Section IIa scientific growth for the therapy of hemophilia A and B.

See Additionally

Insider Buying and Selling by Quarter for Centessa Pharmaceuticals (NASDAQ:CNTA)

This instantaneous information alert was generated by narrative science know-how and monetary information from MarketBeat so as to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account Centessa Prescribed drugs, you may wish to hear this.

MarketBeat retains observe of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they suggest to their purchasers each day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Centessa Prescribed drugs wasn’t on the checklist.

Whereas Centessa Prescribed drugs at the moment has a “Maintain” score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.

View The Five Stocks Here

10 Best Stocks to Own in 2023 Cover



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments